{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-110166","form_type":"8-K","ticker":"ACET","cik":"0001720580","company_name":"Adicet Bio, Inc.","filed_at":"2024-09-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.257592+00:00","generated_at":"2026-05-31T00:47:31.014436+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Adicet opens Phase 1 enrollment for ADI-001 in autoimmune diseases; preliminary data expected H1 2025","bullets":["Phase 1 trial now enrolling lupus nephritis (LN) patients; SLE, SSc, AAV enrollment to open Q4 2024.","FDA granted Fast Track Designation for ADI-001 in relapsed/refractory class III/IV LN.","Plan to report preliminary clinical data in LN, SLE, SSc, and AAV by first half of 2025.","Trial has three arms: LN/SLE, SSc, AAV; single dose of ADI-001 with 28-day DLT window and 24-month follow-up."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-110166","json":"https://secwatch.observer/filing/0000950170-24-110166.json","markdown":"https://secwatch.observer/filing/0000950170-24-110166.md","text":"https://secwatch.observer/filing/0000950170-24-110166.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1720580/000095017024110166/0000950170-24-110166-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1720580/000095017024110166/acet-20240930.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T00:47:31.014436+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}